Telmisartan Impurity: Biphenyl-Benzimidazole Dicarboxylic Acid
Telmisartan Impurity: Biphenyl-Benzimidazole Dicarboxylic Acid
1-((2'-Carboxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-2-propyl-1H-benzo[d]imidazole-6-carboxylic acid is a structurally complex biphenyl-benzimidazole dicarboxylic acid that serves as a key impurity reference standard in the synthesis and quality control of telmisartan, a widely used angiotensin II receptor blocker (ARB).
- SKU
- C195527
- Chemical Name
- 1-((2'-Carboxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-2-propyl-1H-benzo[d]imidazole-6-carboxylic acid
- Compound Class
- Biphenylmethyl benzimidazole dicarboxylic acid
- Primary Application
- Telmisartan impurity reference standard for pharmaceutical QC
- Functional Groups
- Two carboxylic acids, benzimidazole ring, biphenyl moiety, N-alkyl and C-alkyl substituents
- Relevance to API
- Structural analog and potential process-related impurity of telmisartan
Chemical Identity and Structure
1-((2'-Carboxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-2-propyl-1H-benzo[d]imidazole-6-carboxylic acid (Aladdin SKU: C195527) belongs to the benzimidazole class of heterocyclic compounds. Its molecular architecture combines three key pharmacophoric elements: a 4-methylbenzimidazole core bearing a 2-propyl substituent, an N-1 biphenylmethyl linker carrying a 2'-carboxylic acid group on the pendant phenyl ring, and a 6-carboxylic acid substituent on the benzimidazole ring itself.
This dual-carboxylate motif distinguishes it from telmisartan, in which the 6-carboxylic acid of the benzimidazole is present but the biphenyl tetrazole is replaced by a carboxylic acid. The compound is therefore considered a close structural analog of telmisartan and is relevant to understanding the synthetic impurity profile of this active pharmaceutical ingredient (API).
Role as a Pharmaceutical Impurity Reference Standard
During the synthesis of telmisartan, multiple reaction steps involving biphenyl intermediates and benzimidazole cyclization can give rise to process-related impurities. C195527 represents a structurally plausible impurity arising from incomplete or alternative functionalization of the biphenyl carboxylate moiety, making it a critical reference standard for method development and validation.
Regulatory guidelines issued by the ICH (notably ICH Q3A and Q3B) require that pharmaceutical manufacturers identify, characterize, and control impurities in APIs and drug products above defined thresholds. Reference standards such as C195527 enable analytical chemists to develop and validate HPLC and LC-MS methods capable of detecting and quantifying this impurity at trace levels. Accurate impurity profiling is essential for ensuring patient safety and regulatory compliance.
Analytical Applications and Method Development
C195527 is primarily employed as an authentic reference standard in reversed-phase HPLC and LC-MS/MS impurity profiling assays for telmisartan drug substance and drug product. Its two ionizable carboxylic acid groups (pKa values expected in the range typical for aromatic carboxylic acids) confer UV absorbance in the 210–280 nm range, facilitating detection with conventional DAD or UV detectors.
In LC-MS applications, the compound's distinct molecular mass and fragmentation pattern allow unambiguous identification against background matrix components. Researchers developing forced degradation studies or stress testing protocols for telmisartan formulations may also use C195527 to assign chromatographic peaks and confirm structural identity by accurate mass measurement.
Proper handling of this compound requires dissolution in appropriate organic solvents such as DMSO, methanol, or acetonitrile, optionally with the addition of dilute base to fully ionize the carboxylate groups and improve solubility. Stock solutions should be stored under conditions that prevent hydrolytic or oxidative degradation.
Storage, Handling, and Safety Considerations
As with most organic reference standards, C195527 should be stored in a cool, dry environment away from direct light and moisture. Tightly sealed vials under inert atmosphere (nitrogen or argon) are recommended to maximize long-term stability. Researchers should consult the product-specific Safety Data Sheet (SDS) provided by Aladdin Scientific for precise hazard classifications, personal protective equipment requirements, and disposal guidelines.
Standard laboratory precautions apply: use appropriate gloves, eye protection, and work in a well-ventilated area or fume hood when weighing or preparing solutions. Given the compound's carboxylic acid functionality, contact with skin and mucous membranes should be avoided.
Frequently asked questions
What is C195527 used for in pharmaceutical research?
C195527 serves as an authentic impurity reference standard for telmisartan, an angiotensin II receptor blocker (ARB). It is used by analytical chemists to develop, validate, and execute HPLC and LC-MS impurity profiling methods required for regulatory submissions and quality control of telmisartan API and formulations.
How does C195527 differ structurally from telmisartan?
Both compounds share a 4-methyl-2-propyl-1H-benzo[d]imidazole-6-carboxylic acid core linked via an N-1 benzimidazole nitrogen to a biphenylmethyl group. The key difference is that telmisartan bears a tetrazole group on the biphenyl moiety, whereas C195527 carries a carboxylic acid at the corresponding 2'-position, making it a dicarboxylic acid analog.
What solvents are recommended for dissolving C195527?
DMSO, methanol, and acetonitrile are commonly used organic solvents for dissolving benzimidazole carboxylic acid derivatives. Adding a small amount of dilute aqueous base can improve aqueous solubility by ionizing the carboxylate groups. The optimal solvent system should be verified experimentally and must be compatible with the downstream analytical method.
Which regulatory guidelines govern impurity control for telmisartan-related impurities?
ICH Q3A (Impurities in New Drug Substances) and ICH Q3B (Impurities in New Drug Products) provide the framework for identification, qualification, and control thresholds for process-related impurities. Pharmacopoeial monographs (e.g., USP, EP) for telmisartan may also specify individual impurity limits that require certified reference standards for compliance testing.
References
- International Council for Harmonisation. ICH Q3A(R2): Impurities in New Drug Substances. 2006.
- International Council for Harmonisation. ICH Q3B(R2): Impurities in New Drug Products. 2006.
- Aladdin Scientific. Product Datasheet: 1-((2'-Carboxy-[1,1'-biphenyl]-4-yl)methyl)-4-methyl-2-propyl-1H-benzo[d]imidazole-6-carboxylic acid, SKU C195527.
Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.
危险品化学品经营许可证(带存储)